Sublingual Minoxidil Hair Regrowth Breakthrough: Testosterone-Treated Transgender Trial Shows +15.7 Hairs/cm2 Midfrontal Gain Without Lowering Testosterone

A new randomized clinical trial has quietly answered one of the most practical hair-loss questions in gender-affirming care: can you treat testosterone-related androgenetic alopecia without using a drug that interferes with masculinization?

The treatment tested was sublingual minoxidil. Instead of rubbing minoxidil on the scalp or swallowing a standard oral tablet, participants dissolved minoxidil under the tongue. The study focused on transgender and gender-diverse people receiving full-dose testosterone therapy who had mild androgenetic alopecia.

The headline result: after 24 weeks, sublingual minoxidil produced a +15.7 hairs/cm² advantage over placebo in the midfrontal scalp. That matters because frontal thinning is often one of the most distressing testosterone-associated pattern-hair-loss changes, and many patients hesitate to use 5-alpha-reductase inhibitors such as finasteride because of concerns about blocking desired testosterone effects.

This is not a magic cure, and it is not a do-it-yourself dosing plan. But it is one of the most useful human hair-loss studies of 2026 because it studies the exact population that usually gets left out of androgenetic alopecia trials.

What Is It and How Does It Work?

Sublingual minoxidil is minoxidil placed under the tongue, where it can be absorbed through the oral mucosa. The idea is different from both topical minoxidil and standard swallowed oral minoxidil.

Minoxidil itself is a growth-promoting drug used in hair loss. It does not block testosterone or DHT. Instead, it is thought to support hair growth through mechanisms such as potassium-channel activity, improved follicle cycling, growth-factor effects, and stronger anagen behavior.

The sublingual route is interesting because it may change how the drug enters the body:

1. Topical minoxidil depends on scalp application, follicular absorption, and local sulfotransferase activation.
2. Swallowed oral minoxidil enters the gut and liver first, then circulates systemically.
3. Sublingual minoxidil is designed to absorb through tissue under the tongue, potentially changing exposure and tolerability.

For transgender people on testosterone, that distinction matters. A non-hormonal growth stimulant could support hair density without deliberately reducing testosterone, suppressing DHT, or interfering with masculinizing effects.

The Science: A Randomized Trial in Testosterone-Treated Trans People

The new study was published in the Journal of the American Academy of Dermatology and indexed on PubMed as “Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial.”

The trial design was refreshingly direct:

• Participants: 46 transgender and gender-diverse adults receiving full-dose testosterone therapy.
• Randomization: 23 received sublingual minoxidil and 23 received placebo.
• Blind phase dose: sublingual minoxidil 1.35 mg twice daily for 24 weeks.
• Extension phase: all participants then received sublingual minoxidil 2.5 mg twice daily in an open-label extension.
• Measurement method: tattoo-directed phototrichograms, with co-primary endpoints at the midfrontal and vertex scalp.

At week 24, the key controlled result was a +15.7 hairs/cm² midfrontal target-area hair-count advantage for sublingual minoxidil versus placebo. The vertex did not show a significant between-group difference at week 24.

The later open-label phase is also interesting. By week 48, the study reported a net midfrontal improvement from baseline of +12.3 hairs/cm² and a significant vertex gain of +37.9 hairs/cm² compared with baseline.

That pattern suggests the frontal scalp may respond earlier, while vertex improvement may require longer treatment, a higher dose, or both. But because the extension was open-label rather than placebo-controlled, the week-48 numbers should be interpreted as supportive rather than definitive.

Why This Trial Is Different From Most Hair-Loss Research

Most androgenetic alopecia studies are built around cisgender men or cisgender women. That leaves a major evidence gap for transgender people receiving testosterone, even though testosterone therapy can trigger or accelerate pattern hair loss in genetically susceptible people.

The standard androgenetic alopecia logic is often: reduce DHT with finasteride or dutasteride. But that decision can be more complicated in people using testosterone for masculinization. Some patients worry that 5-alpha-reductase inhibition could affect desired changes such as facial hair, body hair, genital growth, mood, libido, or other androgen-mediated effects. The size of those effects varies, and some people still choose finasteride or dutasteride, but the concern is real enough that non-hormonal alternatives are badly needed.

That is why sublingual minoxidil is exciting in this context. It aims to push the follicle toward stronger growth without directly reducing testosterone or DHT production.

What Makes the Result Exciting?

The most exciting part is not only the hair count. It is the combination of three signals:

• Controlled efficacy: the 24-week placebo-controlled phase showed a statistically significant midfrontal hair-count advantage.
• Hormone preservation: the study reported no effect on testosterone concentrations.
• Tolerability: the treatment was described as well tolerated, with no serious adverse events reported.

That makes the study unusually practical. It does not ask trans patients to choose between hair preservation and gender-affirming testosterone therapy. It tests a pathway that may sit alongside testosterone rather than fighting it.

It also reinforces a broader minoxidil lesson: route and dose matter. Prior sublingual-minoxidil research in male androgenetic alopecia suggests dose-dependent effects on hair density and fibre diameter. A 2025 Clinical and Experimental Dermatology analysis reported that sublingual minoxidil 1.35 mg and 4.05 mg increased mean hair fibre diameter in male androgenetic alopecia, while 0.45 mg did not. That supports the idea that sublingual dosing may need to reach a threshold before it meaningfully changes miniaturization biology.

How Safe Is Sublingual Minoxidil?

The new transgender testosterone trial reported no serious adverse events and no change in testosterone concentrations. The authors also deposited supplementary side-effect data for the double-blind phase.

But minoxidil is still a real medication. Low-dose systemic minoxidil can cause side effects such as unwanted facial or body hair growth, dizziness, fluid retention, ankle swelling, headache, palpitations, tachycardia, postural hypotension, and, rarely, more serious cardiovascular issues. Anyone with heart disease, blood-pressure problems, kidney disease, pregnancy potential, or complex medication use needs medical supervision.

The key practical point: well tolerated in a 46-person trial does not mean risk-free for everyone. It means this particular protocol looked encouraging under study conditions.

When Will It Be Available?

Sublingual minoxidil is not a standard over-the-counter hair-loss product. Depending on country and clinician practice, it may involve prescription compounding or specialist supervision. The exact formulation matters, because splitting tablets or improvising under-the-tongue dosing is not the same as using a studied sublingual preparation.

Before this becomes a mainstream option, the field still needs:

• larger multicenter trials in transgender and gender-diverse populations,
• longer follow-up beyond 48 weeks,
• clearer dose-response data for frontal versus vertex scalp,
• direct comparison with topical minoxidil and low-dose oral minoxidil,
• careful cardiovascular monitoring data,
• and patient-reported outcomes focused on dysphoria, satisfaction, adherence, and unwanted hair growth.

Still, this trial moves the conversation forward. It gives clinicians a controlled-data starting point rather than forcing them to extrapolate entirely from cisgender male androgenetic alopecia studies.

How You Can Benefit From This Research Now

If you are on testosterone therapy and noticing hairline or crown thinning, this study gives several practical takeaways.

1. Do not wait until follicles are badly miniaturized. The trial involved mostly mild androgenetic alopecia. Hair treatments generally work better when follicles are still producing visible hairs.
2. Ask about non-hormonal options. If you are concerned about finasteride or dutasteride affecting masculinization, minoxidil-based strategies may be worth discussing with a dermatologist or gender-affirming clinician.
3. Track frontal and vertex areas separately. This study found a clearer midfrontal signal at 24 weeks, while vertex improvement appeared later in the extension phase.
4. Do not DIY sublingual dosing. Minoxidil can affect blood pressure and fluid balance. The route, dose, formulation and monitoring matter.
5. Use objective measurement if possible. Standardized photos, phototrichograms, or trichoscopy are much more reliable than judging from shedding alone.

The bottom line: sublingual minoxidil may be a major new non-hormonal option for testosterone-associated pattern hair loss. In a randomized placebo-controlled trial, it improved midfrontal hair count without reducing testosterone concentrations and with no serious adverse events reported. The next step is bigger, longer research. But for a population that has been underrepresented in hair-loss trials, this is genuinely useful progress.

Sources

• Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil – PubMed
• University of Adelaide record and abstract for the JAAD trial
• Supplementary side-effect data for the sublingual minoxidil testosterone trial – Mendeley Data
• Sublingual minoxidil increases fibre diameter in male androgenetic alopecia – Clinical and Experimental Dermatology
• Sublingual minoxidil 5 mg versus oral minoxidil 5 mg for male androgenetic alopecia – PubMed